Evidence map›Paper›PMID 39567998›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

Dual inhibition of HERs and PD-1 counteract resistance in KRAS

Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben-Lulu, Baisali Bhattacharya and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ofra NovoplanskyThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Sankar JagadeeshanThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Manu PrasadThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Ksenia M YegodayevThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Divyasree MarripatiThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Raghda Abu SharebThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Yariv GreenshpanThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Sooraj MathukkadaThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Talal Ben-LuluThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Baisali BhattacharyaThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Angel PorgadorThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel.
Dexin KongSchool of Pharmaceutical Sciences, Tianjin Medical University, Tianjin, China.
Johannes BrägelmannDepartment of Translational Genomics, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937, Cologne, Germany.
J Silvio GutkindDepartment of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Moshe ElkabetsThe Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 84105, Beer-Sheva, Israel. moshee@bgu.ac.il.ORCID http://orcid.org/0000-0003-3634-9098

Funding

Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCCR01CA247551 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2020 to 2024
$2.5M
Israel Science Foundation 302/21Israel Science Foundation 700/16Israel Science Foundation ISFNCI NIH HHS R01 CA247551United States - Israel Binational Science Foundation #2021055United States - Israel Binational Science Foundation BSF
6 · The paper itself

Abstract

backgroundBasket clinical trials targeting the KRAS

methodsWestern-blotting was used for protein abundance and activation, overexpression, and ligand activation studies to verify the intrinsic mechanism of resistance to KRAS

resultsActivation and upregulation of EGFR and HER2/3 (pan-HERs) are the intrinsic mechanism of resistance to KRAS

conclusionsOur study highlights the critical need for blocking both intrinsic and extrinsic mechanisms of resistance for the prolonged response and shows that such treatment is ineffective in KRAS

Indexed as

Head and Neck NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorDrug Resistance, NeoplasmHumansMiceMutationProgrammed Cell Death 1 ReceptorKRAS protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins p21(ras)AdagrasibCell-autonomousDrug resistanceHead and neck cancerHER signalingKRASG12C mutationPD-L1/PD1SotorasibTumor microenvironment

Identifiers

PMID39567998
PMCPMC11577641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.